Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats. 2016

Soo-Han Lee, and Seung-Hyun Kim, and Yook-Hwan Noh, and Byung-Moon Choi, and Gyu-Jeong Noh, and Woo-Dae Park, and Eun-Jung Kim, and Ik-Hyun Cho, and Chun-Sik Bae
Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University, Seoul, Korea.

Memantine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist used to treat Alzheimer's disease. We investigated memantine pharmacokinetics after oral, IV and patch administration in rats, and compared memantine pharmacokinetics after multiple- or single-dose oral and transdermal administration. Venous blood was collected at preset intervals in single- and multiple-dose studies. Non-compartmental pharmacokinetics was analysed for all formulations. The oral, IV and patch memantine doses were 10 mg/kg, 2 mg/kg and 8.21 ± 0.89 mg/kg, respectively. The maximum plasma concentration was lower and the half-life longer after patch administration than oral and IV administration. Memantine bioavailability was 41 and 63% for oral and patch administration, respectively. Steady state was achieved around 24 hr for oral and patch administration. The mean AUC increased after oral or patch administration from single to multiple dose. The memantine patch formulation displayed a longer duration of action and lower peak plasma concentration. However, drug exposure was similar to the oral formulation at each dose. Additionally, the memantine patch formulation displayed a smaller interindividual variability and lower accumulation than the oral formulation.

UI MeSH Term Description Entries
D008559 Memantine AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent. 1,3-Dimethyl-5-aminoadamantane,1-Amino-3,5-dimethyladamantane,Axura,D-145,D145,Ebixa,Memantin,Memantine Hydrochloride,Namenda,D 145
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

Soo-Han Lee, and Seung-Hyun Kim, and Yook-Hwan Noh, and Byung-Moon Choi, and Gyu-Jeong Noh, and Woo-Dae Park, and Eun-Jung Kim, and Ik-Hyun Cho, and Chun-Sik Bae
April 2009, American journal of veterinary research,
Soo-Han Lee, and Seung-Hyun Kim, and Yook-Hwan Noh, and Byung-Moon Choi, and Gyu-Jeong Noh, and Woo-Dae Park, and Eun-Jung Kim, and Ik-Hyun Cho, and Chun-Sik Bae
January 2011, Journal of biomedical research,
Soo-Han Lee, and Seung-Hyun Kim, and Yook-Hwan Noh, and Byung-Moon Choi, and Gyu-Jeong Noh, and Woo-Dae Park, and Eun-Jung Kim, and Ik-Hyun Cho, and Chun-Sik Bae
December 1987, Journal of clinical pharmacology,
Soo-Han Lee, and Seung-Hyun Kim, and Yook-Hwan Noh, and Byung-Moon Choi, and Gyu-Jeong Noh, and Woo-Dae Park, and Eun-Jung Kim, and Ik-Hyun Cho, and Chun-Sik Bae
December 2018, Journal of veterinary pharmacology and therapeutics,
Soo-Han Lee, and Seung-Hyun Kim, and Yook-Hwan Noh, and Byung-Moon Choi, and Gyu-Jeong Noh, and Woo-Dae Park, and Eun-Jung Kim, and Ik-Hyun Cho, and Chun-Sik Bae
September 2006, Journal of clinical pharmacology,
Soo-Han Lee, and Seung-Hyun Kim, and Yook-Hwan Noh, and Byung-Moon Choi, and Gyu-Jeong Noh, and Woo-Dae Park, and Eun-Jung Kim, and Ik-Hyun Cho, and Chun-Sik Bae
April 1974, Journal of pharmacokinetics and biopharmaceutics,
Soo-Han Lee, and Seung-Hyun Kim, and Yook-Hwan Noh, and Byung-Moon Choi, and Gyu-Jeong Noh, and Woo-Dae Park, and Eun-Jung Kim, and Ik-Hyun Cho, and Chun-Sik Bae
June 2011, Journal of veterinary pharmacology and therapeutics,
Soo-Han Lee, and Seung-Hyun Kim, and Yook-Hwan Noh, and Byung-Moon Choi, and Gyu-Jeong Noh, and Woo-Dae Park, and Eun-Jung Kim, and Ik-Hyun Cho, and Chun-Sik Bae
January 1986, European journal of drug metabolism and pharmacokinetics,
Soo-Han Lee, and Seung-Hyun Kim, and Yook-Hwan Noh, and Byung-Moon Choi, and Gyu-Jeong Noh, and Woo-Dae Park, and Eun-Jung Kim, and Ik-Hyun Cho, and Chun-Sik Bae
December 2011, Veterinary dermatology,
Soo-Han Lee, and Seung-Hyun Kim, and Yook-Hwan Noh, and Byung-Moon Choi, and Gyu-Jeong Noh, and Woo-Dae Park, and Eun-Jung Kim, and Ik-Hyun Cho, and Chun-Sik Bae
January 2001, BMC pharmacology,
Copied contents to your clipboard!